Yahoo Web Search

Search results

1. • 

     Brookfield cancer patient gets ‘a second chance on life’ with stem cells from a Canadian athlete

     The News-Times· 7 days ago

     Submission of a sample to a national donor program sparked an unexpected connection between a...

2. • Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

     WKRN Nashville· 5 days ago

     Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Aleksandra Rizo, M.D ...

3. • MEI Pharma (NASDAQ:MEIP) Coverage Initiated at StockNews.com

     ETF DAILY NEWS· 4 days ago

     Equities researchers at StockNews.com began coverage on shares of MEI Pharma (NASDAQ:MEIP – Get Free Report) in a report released on Wednesday. The brokerage set a “buy” rating on the stock.

4. • Syros Pharmaceuticals (NASDAQ:SYRS) Stock Rating Reaffirmed by HC Wainwright

     ETF DAILY NEWS· 2 days ago

     HC Wainwright restated their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a report issued on Wednesday, Benzinga reports. The firm currently has a $15.00 price ...

5. • Syros Pharmaceuticals (NASDAQ:SYRS) Upgraded by StockNews.com to Hold

     ETF DAILY NEWS· 5 days ago

     StockNews.com upgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) from a sell rating to a hold rating in a research report sent to investors on Wednesday morning. Several other ...

6. • Vanguard Personalized Indexing Management LLC Raises Position in Incyte Co. (NASDAQ:INCY)

     ETF DAILY NEWS· 2 days ago

     Vanguard Personalized Indexing Management LLC boosted its stake in Incyte Co. (NASDAQ:INCY – Free Report) by 30.4% during the fourth quarter, according to its most recent 13F filing with the ...

7. • Q2 2024 EPS Estimates for Syros Pharmaceuticals, Inc. Increased by HC Wainwright (NASDAQ:SYRS)

     ETF DAILY NEWS· 4 days ago

     Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Free Report) – Research analysts at HC Wainwright lifted their Q2 2024 EPS estimates for Syros Pharmaceuticals in a research report issued to clients ...

8. • HC Wainwright Cuts Cullinan Oncology (NASDAQ:CGEM) Price Target to $28.00

     ETF DAILY NEWS· 2 days ago

     Cullinan Oncology (NASDAQ:CGEM – Free Report) had its target price decreased by HC Wainwright from $29.00 to $28.00 in a report released on Thursday morning, Benzinga reports. HC Wainwright ...

9. • Vor Biopharma’s (VOR) Market Outperform Rating Reiterated at JMP Securities

     ETF DAILY NEWS· 5 days ago

     JMP Securities reiterated their market outperform rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research report released on Monday, Benzinga reports. They currently have a ...

10. • Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

      Digital Journal· 7 days ago

      Recent news from the Company's two clinical programs includes: A heavily pretreated breast cancer patient, enrolled in the ALG...its upcoming dose optimization trial in 2Q ...